Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMVAMUNE Safety and Immunogenicity in Vaccinia-Experienced Elderly
NCT00857493Phase 2Completed
- Sponsor
- Bavarian Nordic
- Start
- Jun 2009
- Primary completion
- Aug 2010
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JYNNEOS in smallpox (2 arms), sponsored by Bavarian Nordic. Primary endpoint: Related Serious Adverse Events at 8 weeks. Started Jun 2009; status: completed.
02
Drugs
JYNNEOS
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT00857493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00857493.